156. Lu L. Pathologic and physiologic interactions of bacteria with the gastrointestinal epithelium / L. Lu, W.A. Walker // Am J Clin Nutr. - 2001. - Vol.73. - P. 1124S-1130S.
157. MacDonald T.T. Bacterial regulation of intestinal immune responses / T.T. MacDonald, S. Pettersson // Inflamm Bowel Dis. - 2000. - Vol.6. - P. 116-122.
158. Matsumoto M. Posttranslational phosphorylation of mutant p53 protein in tumor development / M. Matsumoto, M. Furihata, Y. Ohtsuki // Med Mol Morphol. - 2006. - N 39(2). - Р. 79-89.
159. Meining A. Features of gastritis predisposing to gastric adenoma and early gastric cancer / A. Meining, B. Riedl, M. Stolte // J Clin Pathol. - 2002. - N 55. - Р.770-5.
160. Metaanalysis of the relationship between CagA seropositivity and gastric cancer / J.Q. Huang [et al.] // Gastroenterology. - 2003. - Vol. 125. - P. 1636-1644.
161. Moayyedi P. Clinical and economic consequences of dyspepsia in the community / P. Moayyedi, J. Mason // Gut 2002. - N 50 (suppl. 4). - Р. 10-13.
162. Morphometric evaluation of gastric antral atrophy: improvement after cure H. pylori infection / B. Ruiz [et al.] // Scand. J. Gastroenterol. - 2002. - Vol.16 (80). - Р. 1449-1456.
163. Narrow band imaging for the detection of gastric intestinal metaplasia and dysplasia during surveillance endoscopy / L.G. Capelle [et al.] // Dig Dis Sci. - 2010. - N 55(12). - P. 3442-3449.
164. Rationale in diagnosis and screening of atrophic gastritis with stomachspecific plasma biomarkers / L. Agreus [et al.] // Scand. J. Gastroenterol. - 2012. - Vol. 47, N 2. - P. 136-147.
165. O'Morain C. Indications for H. pylori treatment / C. O'Morain // Management of H. pylori infection: The Maastricht 4 Consensus. Symposium 19.UEGW. - Stockholm, 2011. - Oral presentation.
166. Prevalence of atrophic gastritis in dyspeptic patients in Piedmont. A survey using the GastroPanel test / L. Lombardo [et al.] // Clin. Chem. Lab. Med. - 2010. - Vol. 48. - P. 1327-1332.
167. Prevalence of primary clarithromycin resistance in Helicobacter pylori strains over a 15 year period in Italy / V. De Francesco [et al.] // J Antimicrob Chemother. - 2007. - 59. - Р. 783-783.
168. Primary clarithromycin resistance to Helicobacter pylori and therapy failure in children: the experience in West Virginia / Y. Elitsur [et al.] // J. Pediatr. Gastroenterol. Nutr. - 2006. - N 42. - Р. 327-331.
169. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer / H. Ohata [et al.] // Int. J. Cancer. - 2004. - Vol.109 (1). - P. 138-143.
170. Prospective study of physical activity and risk of primary adenocarcinoma of the esophagus and stomach in the EPIC (European Prospective Investigation into Cancer and Nutrition) cohort / J.M. Huerta [et al.] // Cancer Causes Control. - 2010. - Vol. 21. - P. 657-659.
171. Quantitative detection of Helicobacter pylori gene expression in vivo and relationship to gastric pathology / R.M. Jr. Peek [et al.] // Infect Immunol. - 2000. - Vol.68. - P. 5488-5495.
172. Rationale in diagnosis and screening of atrophic gastritis with stomachspecific plasma biomarkers / L. Agreus [et al.] // Scand. J. Gastroenterol. - 2012. - Vol. 47, N 2. - P. 136-147.
173. Relation of Helicobacter pylori infection and lifestyle to the risk of chronic atrophic gastritis: a cross-sectional study in Japan / K. Shibata [et al.] // J. Epidemiol. - 2002. - Vol. 12, N 2. - P. 105-111.
174. Rodgers C. A meta-analysis of the success rate of Helicobacter pylori therapy in Canada / C. Rodgers, S.V. van Zanten // Can J Gastroenterol. - 2007. - N 21(5). - Р. 295-303.
175. Role of Helicobacter pylori cagA (+) strains and specific host immune responses on the development of premalignant and malignant lesions in the gastric cardia / R.M. Jr. Peek [et al.] // Int J Cancer. - 2005. - Vol.82. - P. 520-524.
176. Role of Helicobacter pylori serology in atrophic body gastritis after eradication treatment / E. Lahner, C. Bordi, E. Di Giulio [et al] // Aliment. Pharmacol. Ther. - 2002. - Vol. 16 (3). - P. 507-513.
177. Rugge M. Secondary prevention of gastric cancer / M. Rugge // Gut. - 2007. - N 56. - Р.1646-1647.
178. Salt intake and gastric cancer risk according to Helicobacter pylori infection, smoking, tumor site and histological type / B. Peleteiro [et al.] // Br. J. Cancer. - 2011. - Vol. 104. -P.198-207.
179. Sansonetti P.J. Microbes and microbial toxins: paradigms for microbialmucosal interactions III. Shigellosis: from symptoms to molecular pathogenesis / P.J. Sansonetti // Am J Physiol. - 2001. - Vol.280. - Р. 319-323.
180. Sartor R.B. Intestinal microflora in human and experimental inflammatory bowel disease / R.B. Sartor // Curr Opin Gastroenterol. - 2001. - Vol.17. - P. 324-330.
181. Sequential alterations in gastric biopsies and tumor tissues support the multistep process of carcinogenesis / H. A1-Awadhi [et al.] // Histol Histopathol. - 2011. - N 26(9). - P. 1153-1163.
182. Sequential treatment for Helicobacter pylori eradication in duodenal ulcer patients: improving the cost of pharmacotherapy / C. Hassan [et al.] // Aliment. Pharmacol. Ther. - 2003. - Vol. 18. - P. 641-646.
183. Serologic response to lower-molecular-weight proteins of H. pylori is related to clinical outcome of H. pylori infection in Taiwan / S.C. Shiesh [et al.] // Dig Dis Sci. - 2000. - Vol.45. - P. 781-788.
184. Seropositivity to Helicobacter pylori heat shock protein 60 is strongly associated with intensity of chronic inflammation, particularly in antrum mucosa: an extension of an 18-year follow- up study of chronic gastritis in Saaremaa, Estonia / T. Vorobjova [et al.] // FEMS Immunol Med Microbiol. - 2001. - Vol.30. - P. 143-149.
185. Seroreactivity to 19.5-kDa Antigen in Combination with Absence of Seroreactivity to 35-kDa Antigen is Associated with an Increased Risk of Gastric Adenocarcinoma / T.S. Chua [et al.] // Helicobacter. - 2002. - Vol. 7, N 4. - P. 257-264.
186. Serum anti-Lewis X antibody is associated with VacA seropositivity but not atrophic gastritis in patients with Helicobacter pylori infection / T. Shimoyama [et al.] // Eur J Gastroenterol Hepatol. - 2001. - Vol.13. - P. 227- 231.
187. Sipponen P. Natural history of gastritis and its relationship to peptic ulcer disease / P. Sipponen // Digestion. - 2002. - N 51(Suppl 1). - Р.70 - 5.
188. Sipponen P. Importance of atrophic gastritis in diagnostics and prevention of gastric cancer: application of plasma biomarkers / P. Sipponen, D.Y. Graham // Scand J Gastroenterol. - 2007. - N 42. - Р. 2-10.
189. The action of bismuth against Helicobacter pylori mimics but is not caused by intracellular iron deprivation / M.V. Bland [et al.] //Antimicrob Agents Chemother. - 2004. - N 48(6). - Р.1983-7.
190. The complete genome sequence of the Helicobacter pylori / J.F. Tomb [et al.] // Nature. - 2002. - Vol.378. - P. 539-547.
191. The Helicobacter pylori vacA s1, m1 genotype and cagA is associated with gastric carcinoma in Germany / S. Miehlke [et al.] // Int J Cancer. - 2000. - Vol.87. - P. 322-327.
192. The immuno-inflammatory mechanism for tissue injury in inflammatory bowel disease and Helicobacter pyloriinfected chronic active gastritis. Roles of the mucosal immune system / H. Nagura [et al.] // Digestion. - 2001. - Vol.63. - P. 12-21.
193. The incidence of reflux oesophagitis after cure of Helicobacter pylori in a Japanese population / T. Murai [et al.] // Aliment Pharmacol Ther. - 2000. - Vol.14 (Suppl. 1) . - P. 161-165.
194. The Montreal definition and classification of gastroesophageal reflux disease: A global evidence-based consensus / N. Vakil [et al.] // Am. J. Gastroenterol. - 2006. - Vol. 101, N 8. - P. 1900-1920.
195. The N-terminal 34 kDa fragment of Helicobacter pylori vacuolating cytotoxin targets mitochondria and induces cytochrome c release / A. Galmiche [et al.] // EMBO J. - 2000. - Vol.19. - P. 6361-6370.
196. The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomized study / V. De Francesco [et al.] // Dig. Liver Dis. - 2004. - Vol. 36. - P. 322-326.
197. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of reflux disease / J.J. Vicari [et al.] // Gastroenterology. - 2002. - Vol.115. - P. 50-57.
198. The validity of a biomarker method for indirect detection of gastric mucosal atrophy versus standart histopathoiogy / M. Leja [et al.] // Dig. Dis. Sci. - 2009. - Vol. 54, N 11. - P. 2377-2384.
199. The Vienna classification of gastrointestinal epithelial neoplasia / R.J. Schlemper [et al.] // Gut. - 2000. - Vol. 47. - P. 251-255.
200. Translocation of Helicobacter pylori CagA into gastric epithelial cells by type IV secretion / S. Odenbreit [et al.] // Science. - 2000. - Vol.287. - P. 1497-1500.
201. Uemura N. Helicobacter pylori infection / N. Uemura // N Engl J Med. - 2000. - Vol.315. - P. 584-589.
202. Vakil N. Antimicrobial resistance and eradication strategies for Helicobacter pylori / N. Vakil // Rev Gastroenterol Disord. - 2009. - N 9. - Р. 78-88.
203. Van de Velde C.J.H. What is optimal surgery for gastric cancer? / C.J.H. Van de Velde // 13th World Congress on Gastrointestinal Cancer. - Barcelona, 2011. - P. 131-150.
204. Van Cutsem E. The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO / Worlds Congress on Gastrointestinal Cancer / E. Van Cutsem, M. Dicato, R. Geva // Ann. Oncology. - 2011. - Vol. 22 (suppl. 5). - P. 1-9.
205. Virulence factors of Helicobacter pylori responsible for gastric diseases in Mongolian gerbils / K. Ogura [et al.] // J Exp Med. - 2000. - Vol.192. - P. 1601-1610.
206. Water extract of Helicobacter pylori stimulates interleukin-8 secretion by a human gastric epithelial cell line (JR-St) through protein tyrosine phosphorylation / K. Yakabi [et al.] // J Gastroenterol Hepatol. - 2000. - Vol. 15. - P. 263-270.
207. Webb P.M. Helicobacter pylori as a risk factor for cancer / P.M. Webb // Baillieres Clin Gastroenterol. - 2003. - Vol.9. - P. 553-572.
208. Weck M.N. Prevalence of chronic atrophic gastritis in different parts of the world / M.N. Weck, H. Brenner // Cancer Epidemiol. Biomarkers Prev. - 2006. - Vol. 15, N 6. - P. 1083-1094.
209. Weel J.F. The interrelationship between cytotoxin and Helicobacter pylori-related diseases / J.F. Weel // J Infect Dis. - 2003. - Vol. 163(5). - P. 1151-1155.
210. Werdmuller B.F. Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis / B.F. Werdmuller // Dig Dis Sci. - 2002. - Vol.42. - P. 103-105.
211. Why does Japan have a high incidence of gastric cancer? Comparison of gastritis between UK and Japanese patients / G.M. Naylor, T. Gotoda, M. Dixon [et al.] // Gut. - 2006. - N 55. - Р.1545-57.